Kantonsspital Graubuenden

Chur, Switzerland

9 recruiting

Showing 111 of 11 trials

Recruiting
Phase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled150 locationsNCT07005128
Recruiting
Phase 2

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Metastatic NSCLC - Non-Small Cell Lung Cancer
Swiss Cancer Institute156 enrolled17 locationsNCT07020065
Recruiting
Phase 2

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
Swiss Cancer Institute162 enrolled13 locationsNCT06401980
Recruiting
Phase 1

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer
Amgen479 enrolled57 locationsNCT04221542
Recruiting
Not Applicable

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Non-small Cell Lung Cancer (NSCLC)Stage IV
Swiss Cancer Institute128 enrolled7 locationsNCT06114108
Recruiting
Phase 3

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 1

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Amgen60 enrolled11 locationsNCT07140900
Recruiting
Phase 3

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC200 enrolled26 locationsNCT05815927
Recruiting
Phase 1

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Extensive-stage Small-cell Lung Cancer
Amgen220 enrolled30 locationsNCT06598306
Recruiting
Not Applicable

AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

Metastatic Breast Cancer
Breast International Group1,000 enrolled52 locationsNCT02102165
Recruiting

E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

Cancer
European Organisation for Research and Treatment of Cancer - EORTC2,000 enrolled77 locationsNCT03818503